comparemela.com

Latest Breaking News On - Richardw pascoe - Page 1 : comparemela.com

Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) – Cantor Fitzgerald reduced their FY2023 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Tuesday, May 16th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($1.45) for the year, down from their prior estimate […]

Richardw-pascoe
Matthewr-plooster
Zevra-therapeutics-inc
Nasdaq
Securities-exchange-commission
Cantor-fitzgerald
Maxim-group
Zevra-therapeutics
Get-rating
Zevra-therapeutic
Exchange-commission

Zevra's Leading Drug Candidate for IH Treatment Advancing

 Zevra Therapeutics announced KP1077, its leading clinical candidate for treating idiopathic hypersomnia, is advancing. 

Christal-mickle
Richardw-pascoe
Zevra-therapeutics-inc
Investigational-new-drug

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Down 10%

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) traded down 10% during trading on Tuesday . The stock traded as low as $4.41 and last traded at $4.43. 351,489 shares changed hands during mid-day trading, an increase of 51% from the average session volume of 233,420 shares. The stock had previously closed at $4.92. Analyst Upgrades […]

Richardw-pascoe
Matthewr-plooster
Nasdaq
Zevra-therapeutics-inc
Maxim-group
Securities-exchange-commission
Zevra-therapeutics-company-profile
Zevra-therapeutics
Get-rating
Therapeutics-trading-down
Director-matthew

StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)

StockNews.com started coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock. Zevra Therapeutics Stock Performance Zevra Therapeutics has a 52-week low of $4.00 and a 52-week high of $6.92. The firm has […]

United-states
America
Richardw-pascoe
Securities-exchange-commission
Renaissance-technologies
Kempharm-inc
York-mellon-corp
America-corp
Zevra-therapeutics
Get-rating
Exchange-commission

StockNews.com Begins Coverage on Zevra Therapeutics (NASDAQ:KMPH)

StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report released on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock. Zevra Therapeutics Price Performance Zevra Therapeutics has a one year low of $4.00 and a one year high of $6.92. The company has a […]

Richardw-pascoe
Securities-exchange-commission
Kempharm-inc
Pensionmark-financial-group
Kovack-advisors-inc
Zevra-therapeutics
Get-rating
Exchange-commission
Capital-management
Financial-group
Ligand-activated

vimarsana © 2020. All Rights Reserved.